1a:I[176881,["/_next/static/chunks/0mrot~1lqq2vw.js","/_next/static/chunks/0tq.~wsodzzyo.js","/_next/static/chunks/0i.l9589uvx0j.js","/_next/static/chunks/0i0f3lqsvi7s~.js","/_next/static/chunks/0ixfnn8kdcc6i.js"],"default"] 1c:I[60790,["/_next/static/chunks/0mrot~1lqq2vw.js","/_next/static/chunks/0tq.~wsodzzyo.js","/_next/static/chunks/0i.l9589uvx0j.js","/_next/static/chunks/0i0f3lqsvi7s~.js","/_next/static/chunks/0ixfnn8kdcc6i.js"],"default"] 1d:I[691915,["/_next/static/chunks/0mrot~1lqq2vw.js","/_next/static/chunks/0tq.~wsodzzyo.js","/_next/static/chunks/0i.l9589uvx0j.js","/_next/static/chunks/0i0f3lqsvi7s~.js","/_next/static/chunks/0ixfnn8kdcc6i.js"],"default"] 1e:I[202116,["/_next/static/chunks/0mrot~1lqq2vw.js","/_next/static/chunks/0tq.~wsodzzyo.js","/_next/static/chunks/0i.l9589uvx0j.js","/_next/static/chunks/0i0f3lqsvi7s~.js","/_next/static/chunks/0ixfnn8kdcc6i.js","/_next/static/chunks/0tni2t5hh-dby.js"],"default"] 1f:I[27201,["/_next/static/chunks/0mrot~1lqq2vw.js","/_next/static/chunks/0tq.~wsodzzyo.js","/_next/static/chunks/0i.l9589uvx0j.js","/_next/static/chunks/0i0f3lqsvi7s~.js"],"IconMark"] 1b:T460,

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.

The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.

It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia.

The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001.

MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

No Dividend Data Available